Spherix (SPEX) said initial data from a late-stage trial of its type 2 oral diabetes drug Naturlose showed a significant drop in blood glucose level, the trial's main goal. The biotech said it remained on target to finish the trial and submit a new drug application in '10. Shares more than doubled intraday before closing just 3 cents higher at 2.03.